FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891760302> ?p ?o ?g. }

• W2891760302 endingPage "k3529" @default.
• W2891760302 startingPage "k3529" @default.
• W2891760302 abstract "To evaluate the relative efficacy of programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors versus conventional drugs in patients with cancer that were PD-L1 positive and PD-L1 negative.Meta-analysis of randomised controlled trials.PubMed, Embase, Cochrane database, and conference abstracts presented at the American Society of Clinical Oncology and European Society of Medical Oncology up to March 2018.Studies of PD-1 or PD-L1 inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) that had available hazard ratios for death based on PD-L1 positivity or negativity were included. The threshold for PD-L1 positivity or negativity was that PD-L1 stained cell accounted for 1% of tumour cells, or tumour and immune cells, assayed by immunohistochemistry staining methods.4174 patients with advanced or metastatic cancers from eight randomised controlled trials were included in this study. Compared with conventional agents, PD-1 or PD-L1 inhibitors were associated with significantly prolonged overall survival in both patients that were PD-L1 positive (n=2254, hazard ratio 0.66, 95% confidence interval 0.59 to 0.74) and PD-L1 negative (1920, 0.80, 0.71 to 0.90). However, the efficacies of PD-1 or PD-L1 blockade treatment in patients that were PD-L1 positive and PD-L1 negative were significantly different (P=0.02 for interaction). Additionally, in both patients that were PD-L1 positive and PD-L1 negative, the long term clinical benefits from PD-1 or PD-L1 blockade were observed consistently across interventional agent, cancer histotype, method of randomisation stratification, type of immunohistochemical scoring system, drug target, type of control group, and median follow-up time.PD-1 or PD-L1 blockade therapy is a preferable treatment option over conventional therapy for both patients that are PD-L1 positive and PD-L1 negative. This finding suggests that PD-L1 expression status alone is insufficient in determining which patients should be offered PD-1 or PD-L1 blockade therapy." @default.
• W2891760302 created "2018-09-27" @default.
• W2891760302 creator A5027339105 @default.
• W2891760302 creator A5066294981 @default.
• W2891760302 date "2018-09-10" @default.
• W2891760302 modified "2023-10-10" @default.
• W2891760302 title "Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis." @default.
• W2891760302 cites W1964435302 @default.
• W2891760302 cites W2028433016 @default.
• W2891760302 cites W2039123767 @default.
• W2891760302 cites W2042699075 @default.
• W2891760302 cites W2098923148 @default.
• W2891760302 cites W2104347254 @default.
• W2891760302 cites W2117692326 @default.
• W2891760302 cites W2125435699 @default.
• W2891760302 cites W2125988127 @default.
• W2891760302 cites W2128035403 @default.
• W2891760302 cites W2156353875 @default.
• W2891760302 cites W2157823046 @default.
• W2891760302 cites W2222086386 @default.
• W2891760302 cites W2293531514 @default.
• W2891760302 cites W2302137442 @default.
• W2891760302 cites W2346108121 @default.
• W2891760302 cites W2516096091 @default.
• W2891760302 cites W2529484692 @default.
• W2891760302 cites W2556988398 @default.
• W2891760302 cites W2557730509 @default.
• W2891760302 cites W2559382297 @default.
• W2891760302 cites W2560367415 @default.
• W2891760302 cites W2562305489 @default.
• W2891760302 cites W2567564314 @default.
• W2891760302 cites W2572174216 @default.
• W2891760302 cites W2582073526 @default.
• W2891760302 cites W2588681363 @default.
• W2891760302 cites W2588916311 @default.
• W2891760302 cites W2593839194 @default.
• W2891760302 cites W2744419411 @default.
• W2891760302 cites W2747107882 @default.
• W2891760302 cites W2762777471 @default.
• W2891760302 cites W2765240211 @default.
• W2891760302 cites W2765696340 @default.
• W2891760302 cites W2770609569 @default.
• W2891760302 cites W2772859838 @default.
• W2891760302 cites W2777461561 @default.
• W2891760302 cites W2790574591 @default.
• W2891760302 cites W2791483720 @default.
• W2891760302 cites W2792893181 @default.
• W2891760302 cites W2793180707 @default.
• W2891760302 cites W3022903699 @default.
• W2891760302 doi "https://doi.org/10.1136/bmj.k3529" @default.
• W2891760302 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6129950" @default.
• W2891760302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201790" @default.
• W2891760302 hasPublicationYear "2018" @default.
• W2891760302 type Work @default.
• W2891760302 sameAs 2891760302 @default.
• W2891760302 citedByCount "312" @default.
• W2891760302 countsByYear W28917603022018 @default.
• W2891760302 countsByYear W28917603022019 @default.
• W2891760302 countsByYear W28917603022020 @default.
• W2891760302 countsByYear W28917603022021 @default.
• W2891760302 countsByYear W28917603022022 @default.
• W2891760302 countsByYear W28917603022023 @default.
• W2891760302 crossrefType "journal-article" @default.
• W2891760302 hasAuthorship W2891760302A5027339105 @default.
• W2891760302 hasAuthorship W2891760302A5066294981 @default.
• W2891760302 hasBestOaLocation W28917603021 @default.
• W2891760302 hasConcept C121608353 @default.
• W2891760302 hasConcept C126322002 @default.
• W2891760302 hasConcept C143998085 @default.
• W2891760302 hasConcept C207103383 @default.
• W2891760302 hasConcept C2775949291 @default.
• W2891760302 hasConcept C2777381376 @default.
• W2891760302 hasConcept C2777701055 @default.
• W2891760302 hasConcept C2777742743 @default.
• W2891760302 hasConcept C2780030458 @default.
• W2891760302 hasConcept C2780057760 @default.
• W2891760302 hasConcept C2781053074 @default.
• W2891760302 hasConcept C44249647 @default.
• W2891760302 hasConcept C71924100 @default.
• W2891760302 hasConceptScore W2891760302C121608353 @default.
• W2891760302 hasConceptScore W2891760302C126322002 @default.
• W2891760302 hasConceptScore W2891760302C143998085 @default.
• W2891760302 hasConceptScore W2891760302C207103383 @default.
• W2891760302 hasConceptScore W2891760302C2775949291 @default.
• W2891760302 hasConceptScore W2891760302C2777381376 @default.
• W2891760302 hasConceptScore W2891760302C2777701055 @default.
• W2891760302 hasConceptScore W2891760302C2777742743 @default.
• W2891760302 hasConceptScore W2891760302C2780030458 @default.
• W2891760302 hasConceptScore W2891760302C2780057760 @default.
• W2891760302 hasConceptScore W2891760302C2781053074 @default.
• W2891760302 hasConceptScore W2891760302C44249647 @default.
• W2891760302 hasConceptScore W2891760302C71924100 @default.
• W2891760302 hasLocation W28917603021 @default.
• W2891760302 hasLocation W28917603022 @default.
• W2891760302 hasOpenAccess W2891760302 @default.
• W2891760302 hasPrimaryLocation W28917603021 @default.
• W2891760302 hasRelatedWork W2584071843 @default.
• W2891760302 hasRelatedWork W2615260918 @default.

• next